J. Aschan, TREATMENT OF MODERATE TO SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE - A RETROSPECTIVE ANALYSIS, Bone marrow transplantation, 14(4), 1994, pp. 601-607
Seventy-one patients with moderate to severe acute GVHD after BMT were
analysed retrospectively, At the start of therapy 96% of the patients
had rashes, 45% liver abnormalities and 54% gut dysfunctions. Forty-f
our patients (62%) had been treated for grade I GVHD with systemic cor
ticosteroids. First therapy for moderate to severe acute GVHD was with
corticosteroids (n = 59), psoralen with ultraviolet light (PUVA) (n =
14), cyclosporin (CsA) (n = 10), antithymocyte globulin (ATG) (n = 7)
, methotrexate (MTX) (n = 2), monoclonal antibodies (n = 1) or thalido
mide (n = 1). In 18 of these patients two or more agents were combined
. Resolution of skin disease and evaluable liver and gut disease were
seen in 48%, 44% and 47% of cases, respectively. Overall complete reso
lution was seen in 37%. Thirty-two patients received a second treatmen
t, resulting in complete resolution in 31%. Patients with a complete r
esponse had an actuarial transplant-related mortality of 37% compared
with 82% or worse for patients with other outcomes (p less than or equ
al to 0.003). Combined treatment was superior to ATG, but not better t
han corticosteroids. In multivariate analysis a low total sum severity
score was the only factor associated with complete response (p = 0.02
). AML diagnosis (p = 0.01) and GVHD of the liver (p = 0.02) were inde
pendent risk factors for treatment failure.